Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Treatment of NPM1-mutated AML: intensive standard treatment

Christoph Röllig • 26 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Gemtuzumab ozogamicin Venetoclax
VIALE-A VIALE-C

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the value of intensive chemotherapy compared with novel targeted treatments for NPM1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christoph Röllig

2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023
1:45
HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig • 11 Dec 2023
2:26
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig • 11 Dec 2023
2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals